TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Striatal DAT occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurotransmitter outcomes
Primary endpoint: Gallbladder volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average TEWL measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: chronotropic response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PWV and arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 35 day mortality
Endpoint domain: Mortality/survival
Primary endpoint: 35 day reinfarction rate
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital admissions due to attacks
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: TEWL reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: stratum corneum hydration improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ICLL length increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: RCVM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rMSSD(3‐5min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete heartburn relief rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 70-point response at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of global CV risk assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deterrence of experimentation with waterpipe tobacco products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Promotion of cessation among non-established users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative mean refractive spherical equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative mean corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean induced positive spherical aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted life-year (QALY)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Life-year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: risk of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risky decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported effort on cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean reduction in corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean refractive astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frenulum sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of muscle fasciculations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum amplitude of muscle action potential (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative serum CK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal pain frequency
Endpoint domain: Adverse events/effects
Primary endpoint: overall hospitalization costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SDQ conduct scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD hyperactivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: overall satisfaction with nursing care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: breastfeeding knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: breastfeeding at six weeks after delivery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression of radiographic damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of primary postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in maternal BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in the position of the lower right first molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average maximum heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average maximum systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average time to post‐ECT recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum transferrin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: referrals for fetal surveillance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: decrease in haemoglobin after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of transfused patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: level of serum AFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve (AUCinfinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum serum concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition to sexual activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referrals to CAIM modalities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 12-month sexual function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incontinence severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in average mean segment diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to 0.1 mV ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average step count during PODs 1-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with decision-making
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with physician communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: body weight improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD117 antigen expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pruritus discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain activation during recognition of face-name pairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in SPT size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in peanut-specific IgG(4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in FoxP3(hi): FoxP3(intermediate) CD4+ CD25+ T cells ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pyruvate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total serum IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thyroid size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid growth stimulating immunoglobulins levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive subjective measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak pupil diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentrations of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-treatment pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hindrance in mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self care and daily activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Tunnel enlargement on the tibial side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior and rotational laxity of the operated knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL levels improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL/HDL ratios improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MAC of halothane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAC of enflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of minimal sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downregulation of CCL20 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Downregulation of IL22 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apgar score at 1 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neonatal outcomes
Primary endpoint: PDSS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean POGO score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal view worsening
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in hypernasality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in nasal emission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in velopharyngeal closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination between LGE(+) and LGE(‐) T1 ‐maps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of diabetes symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful response in neuropathic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement of daily life activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severity of dysphonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased movements into the TTZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired verbal self-monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to neutrophil engraftment (ANC > 0.5 x 10(9)/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma glucose level 1 h after ingestion of 50 g of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean ex vivo residence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolonged systemic circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance improvement in young water polo players
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rates of cCBT
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: improvements in motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological flexibility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidences of severe changes of HR and MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AaDO(2) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching serum phosphorus target of ≤5.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxygen requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in theta power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increases in alpha power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Withdrawal-induced adverse effects on subjective mood
Endpoint domain: Adverse events/effects
Primary endpoint: Blood pressure return to healthy state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraoperative propofol and fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moderate hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: severe hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: PACU bypass to phase 2 recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAS score >4
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean fentanyl use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remodeling of grafted material
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean time for conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrophysiological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of death and/or requiring transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in KOOS symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in KOOS sport and recreation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in WOMAC stiffness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Week 52 responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or rehospitalization for any reason at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Death or rehospitalization for cardiovascular or renal reasons at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: turbidimetric platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: non-Q-wave myocardial infarction
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability of psychiatric diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of seborrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subjective assessments for skin texture and acne scars
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Higher antibody titres against HAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reductions in plasma total immunoglobulin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in hypoglycemia (<70 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median duration of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global CBF change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean radiation dose to the testis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD20 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: median powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total sample size
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median reported effect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lund-Mackay score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index response (≥ 5-point improvement from baseline)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: static Physician Global Assessment response (clear or almost clear)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPI score
Endpoint domain: Mortality/survival
Primary endpoint: QOL change scores in peace-spiritual scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional QOL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall lesion detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of problems in verbal communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: listening experience preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NAA/Cho and NAA/Cr ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in SSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation motives of Enjoyment and Revitalization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: no-show attendance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D and SF-6D mean scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median scores of EQ-5D and SF-6D
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Intra-class correlation of EQ-5D and SF-6D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of blastomeres per embryo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphology score per embryo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average embryo score parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free of emetic sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Offspring IQ in the lowest 10%
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Use of RT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attention differences normalised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attained weight at 18 mo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of respiratory infections
Endpoint domain: Adverse events/effects
Primary endpoint: implant probing pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: well-being of persons with MCI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Distance walked during walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes